Use of chronic kidney disease to enhance prediction of cardiovascular risk in those at medium risk

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Chia, Yook Chin ^a   Lim, Hooi Min ^a   Ching, Siew Mooi ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; ETHNICITY; FEMALE; FRAMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INTERMEDIATE RISK POPULATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING HABIT; AGED; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; MIDDLE AGED; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84949458222     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141344     Document Type: Article

References (33)

1. Anand S, Shivashankar R, Ali MK, Kondal D, Binukumar B, Montez-Rath ME, et al. Prevalence of chronic kidney disease in two major Indian cities and projections for associated cardiovascular disease. Kidney international. 2015.
2. Hooi LS, Ong LM, Ahmad G, Bavanandan S, Ahmad NA, Naidu BM, et al. A population-based study measuring the prevalence of chronic kidney disease among adults in West Malaysia. Kidney international. 2013; 84(5):1034-40. doi: 10.1038/ki.2013.220
3. Nagata M, Ninomiya T, Doi Y, Yonemoto K, Kubo M, Hata J, et al. Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: The Hisayama Study. Nephrology Dialysis Transplantation. 2010; 25(8):2557-64.
4. Ong-Ajyooth L, Vareesangthip K, Khonputsa P, AekplakornW. Prevalence of chronic kidney disease in Thai adults: a national health survey. BMC nephrology. 2009; 10:35. doi: 10.1186/1471-2369-10-35
5. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108(17):2154-69.
6. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. Journal of the American Society of Nephrology: JASN. 2004; 15(5):1307-15.
7. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2004; 44(2):198-206.
8. Olechnowicz-Tietz S, Gluba A, Paradowska A, Banach M, Rysz J. The risk of atherosclerosis in patients with chronic kidney disease. Int Urol Nephrol. 2013; 45(6):1605-12. doi: 10.1007/s11255-013-0407-1
9. Schiffrin EL, Lipman ML, Mann JFE. Chronic Kidney Disease: Effects on the Cardiovascular System. Circulation. 2007; 116(1):85-97.
10. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998 to 1999. Journal of the American Society of Nephrology. 2005; 16(2):489-95.
11. Chia YC. Review of tools of cardiovascular disease risk stratification: interpretation, customisation and application in clinical practice. Singapore medical journal. 2011; 52(2):116-23.
12. Chia YC, Gray SYW, Ching SM, Lim HM, Chinna K. Validation of the Framingham general cardiovascular risk score in a multiethnic Asian population: a retrospective cohort study. BMJ Open. 2015; 5(5).
13. Khalili D, Hadaegh F, Soori H, Steyerberg EW, Bozorgmanesh M, Azizi F. Clinical Usefulness of the Framingham Cardiovascular Risk Profile Beyond Its Statistical Performance: The Tehran Lipid and Glucose Study. American journal of epidemiology. 2012.
14. Zomer E, Owen A, Magliano DJ, Liew D, Reid C. Validation of two Framingham cardiovascular risk prediction algorithms in an Australian population: the 'old' versus the 'new' Framingham equation. European journal of cardiovascular prevention and rehabilitation: official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 2011; 18(1):115-20.
15. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study. Circulation. 2008; 117(6):743-53. doi: 10.1161/CIRCULATIONAHA.107.699579
16. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Annals of internal medicine. 2009; 150(9):604-12.
17. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter, Suppl 2013(3):1-150.
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206-52.
19. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ (Clinical research ed). 2010; 341:c4986.
20. Go A, Chertow G, Fan D, McCulloch C, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305.
21. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M. Chronic kidney disease and mortality risk: a systematic review. Journal of the American Society of Nephrology: JASN. 2006; 17(7):2034-47.
22. Zalba G, Fortuño A, Díez J. Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrology Dialysis Transplantation. 2006; 21(10):2686-90.
23. Zhang L, Zuo L, Wang F, Wang M, Wang S, Lv J, et al. Cardiovascular disease in early stages of chronic kidney disease in a Chinese population. Journal of the American Society of Nephrology: JASN. 2006; 17(9):2617-21.
24. Hitha B, Pappachan JM, Pillai HB, Sujathan P, Ramakrishna CD, Jayaprakash K, et al. Microalbuminuria in patients with essential hypertension and its relationship to target organ damage: an Indian experience. Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2008; 19(3):411-9.
25. Weiner DE, Tighiouart H, Griffith JL, Elsayed E, Levey AS, Salem DN, et al. Kidney Disease, Framingham Risk Scores, and Cardiac and Mortality Outcomes. The American Journal of Medicine. 2007; 120 (6):552.e1-e8.
26. Anand SS, Yusuf S, Vuksan V, Devanesen S, Teo KK, Montague PA, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). The Lancet. 2000; 356(9226):279-84.
27. Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, et al. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Annals of internal medicine. 2011; 154(5):310-8. doi: 10.7326/0003-4819-154-5-201103010-00005
28. Chang A, Kramer H. Should eGFR and albuminuria be added to the Framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction. Nephron Clinical practice. 2011; 119(2): c171-7; discussion c7-8. doi: 10.1159/000325669
29. Drawz PE, Baraniuk S, Davis BR, Brown CD, Colon PJ Sr., Cujyet AB, et al. Cardiovascular risk assessment: addition of CKD and race to the Framingham equation. American heart journal. 2012; 164 (6):925-31.e2. doi: 10.1016/j.ahj.2012.09.003
30. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women. New England Journal of Medicine. 2000; 342 (12):836-43.
31. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107(3):499-511.
32. Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-Analysis. Jama. 2012; 308(8):796-803. doi: 10.1001/jama.2012.9630
33. Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F, et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. Journal of hypertension. 2009; 27(12):2458-64. doi: 10.1097/HJH.0b013e328330b845